Takeda Pharmaceutical (NYSE:TAK) Reaches New 12-Month High – What’s Next?

Takeda Pharmaceutical Company Limited (NYSE:TAK)’s stock price reached a new 52-week high during mid-day trading on Monday . The company traded as high as $15.31 and last traded at $15.12, with a volume of 2903073 shares changing hands. The stock had previously closed at $15.16.

Takeda Pharmaceutical Stock Up 0.3 %

The firm has a fifty day moving average of $14.04 and a 200-day moving average of $13.91. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The firm has a market cap of $47.89 billion, a P/E ratio of 37.63, a price-to-earnings-growth ratio of 0.24 and a beta of 0.46.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. On average, equities research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. First Trust Advisors LP grew its holdings in Takeda Pharmaceutical by 2.0% during the fourth quarter. First Trust Advisors LP now owns 3,240,932 shares of the company’s stock worth $42,910,000 after purchasing an additional 62,718 shares during the period. FMR LLC boosted its stake in shares of Takeda Pharmaceutical by 10.9% during the 3rd quarter. FMR LLC now owns 2,908,918 shares of the company’s stock worth $41,365,000 after acquiring an additional 286,052 shares during the period. Van ECK Associates Corp increased its holdings in shares of Takeda Pharmaceutical by 1.6% during the 4th quarter. Van ECK Associates Corp now owns 2,210,428 shares of the company’s stock worth $29,266,000 after acquiring an additional 35,192 shares during the last quarter. Northern Trust Corp raised its stake in Takeda Pharmaceutical by 14.6% in the 4th quarter. Northern Trust Corp now owns 1,873,588 shares of the company’s stock valued at $24,806,000 after acquiring an additional 238,161 shares during the period. Finally, Soleus Capital Management L.P. lifted its holdings in Takeda Pharmaceutical by 136.0% during the 4th quarter. Soleus Capital Management L.P. now owns 1,180,000 shares of the company’s stock valued at $15,623,000 after purchasing an additional 680,000 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.